Navigation Links
Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy
Date:12/16/2011

Accelerated partial breast irradiation using brachytherapy (APBIb) for the treatment of breast cancer has been rapidly increasing over the last several years in the U.S. as an alternative to standard whole-breast irradiation (WBI), according to a study published December 16th in the Journal of the National Cancer Institute.

Various types of APBI recurrence (external beam radiation, intraoperative radiotherapy, brachytherapy using multiple interstitial catheters, or intracavitary brachytherapy using a balloon catheter) deliver radiation to breast tissue at the highest risk of recurrence. Advantages of these techniques include decreased treatment time and less radiation to uninvolved portions of the breast and normal tissues. Disadvantages of APBI include the possibility that tumor cells in a different part of the breast will remain untreated, which could lead to increased local recurrence. Because of the potential limitations of APBI, in 2009 the American Society for Radiation Oncology (ASTRO) convened a task force of breast cancer experts to develop criteria for use of APBI off-protocol. They proposed three groups of APBI appropriateness: suitable, cautionary and unsuitable, based on patient characteristics and clinical factors.

Because of the growing popularity of APBIb in particular, Jona Hattangadi, M.D., of the Department of Radiation Oncology at the Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues performed a retrospective analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database of women who had received either APBIb or WBI between 2000 and 2007. In line with ASTRO guidelines, the researchers classified the 138,815 women as "suitable", "cautionary", or "unsuitable" for APBIb.

The researchers found that 3,576 of the 138,815 patients had received APBIb: 32% of whom would have been considered suitable, 29.6% cautionary, and 36.2% unsuitable. The overall use of APBIb increased from 0.4% in 2000 to 6.6% in 2007. There was a wide range of utilization patterns across the United States with specific geographic regions having higher APBIb use despite other patient and clinical factors. There were also substantial racial and ethnic disparities with respect to APBIb use. White women were more likely to get this treatment than black women among "cautionary" or "unsuitable" patients; and or women living in cities were more likely to get it than those in rural areas even though it would potentially provide greater convenience for the rural women. The authors conclude "the wide disparity in use of APBIb suggests that unwarranted variationpractice variation not explained by illness, patient preference, or evidence-based medicinemay be present. Future studies of APBIb use will help elucidate whether patterns change as [the ASTRO guidelines] diffuse into practice and whether the regional and temporal changes in APBIb cost, reimbursement, and insurance coverage affect utilization."

In an accompanying editorial Simona F. Shaitelman, M.D., at the Department of Radiation Oncology at the University of Texas M.D. Anderson Cancer Center, notes that it is reassuring that the authors found the fastest increase in utilization among patients classified as "suitable," even if the majority of patients undergoing APBIb in their study were not classified as suitable. Shaitelman also comments on the authors' suggestion that financial interests that might be driving usage and notes that reimbursement was decreased for the procedure after the end of the period of the study. She writes, "Moving forward, it will be useful to analyze more recent trends in the use of APBI and to document whether such changes in financial remuneration are indeed associated with the delivery of APBI." Shaitelman also concludes that more studies of the effectiveness of APBI are needed. "Although population based studies allow us to reflect on changes in patterns of practice, we are still left eagerly awaiting the results of large randomized trials that compare patients outcomes with WBI vs APBI."


'/>"/>

Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. For back, neck pain, artificial disc replacement has cost, outcome advantages over fusion surgery
2. New Polio Vaccine Shows Major Advantages: Study
3. Comparison shows robot-assisted option offers advantages for kidney surgery
4. Policymakers should prepare for major uncertainties with Medicaid expansion
5. Diagnosis uncertainty increases anxiety in patients
6. The Worst Is Over, but the Road to Growth Is Uncertain - The 17th Annual CFO Rising Conference & Exhibition
7. Supercomputer reveals new details behind drug-processing protein model
8. Researchers search for culprit behind dry eyes, mouths and more
9. Unvaccinated Kids Behind Largest U.S. Measles Outbreak in Years: Study
10. Antioxidants Not Behind Red Wines Healthy Effect on Heart: Study
11. Scientists Discover Key Gene Mutation Behind Lou Gehrigs Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April ... in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the ... lives with Parkinson’s disease and is the architect of this informative event to raise ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... President George H. Van Allen have signed a joint enrollment and degree completion ... seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... host, Swirl, A Wine Tasting Event at the La Gorce Country Club in ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Calif. , Feb. 5, 2016  Syneron ... global aesthetic device company, announced today that ... Candela North America, is scheduled to participate in ... Healthcare Conference on February 11, 2016 in ... will allow institutional investors to meet with the ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology: